ZPL-389 is a small molecule,selective histamine H4 receptor antagonist, suitable for once daily oral administration. A Phase 2a proof of concept study in atopic dermatitis has recently been completed. ZPL-389 resulted in a clinically and statistically significant decrease in inflammation compared to placebo. At week 8, ZPL -389 reduced EASI (Eczema Area and Severity Index) by 50% (placebo: 27%, (p=0.01)). ZPL389 was found to be well tolerated with a safety profile comparable to placebo. A Phase 2a proof of concept study in psoriasis is ongoing. ZPL-389 has potential to show better efficacy and tolerability for patients not served by in-line or pipeline biologic therapies.
ZPL-521 is a potent inhibitor of cPLA2, key target at top of the arachidonic acid inflammation cascade. Inhibition of cPLA2a is expected to inhibit key mediators of inflammation, thereby providing the greatest level of efficacy and as a topical treatment it ensures excellent safety by minimising systemic exposure.
ZPL-521 has the potential to provide AD patients with a powerful and safe, non-steroid treatment suitable for chronic use.
Expected near term development milestones
- ZPL-389 Phase 2a atopic dermatitis - Data presented at EAACI
- ZPL-389 Phase 2b atopic dermatitis - In planning
- ZPL-389 Phase 2a psoriasis - Completion H1 2017
- ZPL-521 Phase 1/2a atopic dermatitis - Start H2 2016
- ZPL-521 Phase 1/2a atopic dermatitis - Completion H1 2017